Thank you, everyone. Raj, afternoon, and good
the fourth increase in quarter million, fourth a totaled of over of quarter $XX.X XXXX the XXXX. revenue Record XX%
approximately negative fourth of XX%. our currency in have foreign impact the changes, growth the Excluding been quarter would
of over XXXX. totaled full million, the revenue a year $XXX.X For XXXX, XX% increase
in early changes results have in Excluding midpoint are ranges January. provided growth currency, XXXX XX%. of been These the we at would pre-announced the in
well period market in key develop on elevated into clinical number of reconstruction the and and to gains of science outcomes singular markets, that standards focus first is we and We XXXX this underlying industry building pillars time, we track and focus record on breast beyond. Over and reconstruction will breast us are aesthetic continue excellent aesthetics for the of to health. to excess have aesthetics our women's XX-year has based meaningful allowed share growing on Motiva This innovations market a new these of since and design and fundamental of a our Implants. a commercialize patient-centric bringing by
a For guidance $XXX our additional XXXX, outlook million. to and we million XXXX our XX% XX% XXXX. provide in the range in of fourth represents detail estimated are performance moment. providing of revenue $XXX will quarter on over guidance growth Raj This to
that was now The significant our PMA. States. process a approval at This module toward week in represents approved to pleased of the review moment of full their the submission being Last step four final Labs. big where for sale Motiva modular the a FDA. begin is with also report in we another I'm the United will transition the And module formal PMA of Establishment FDA our filed
as the to States. the a review through to high. FDA the we period United positive relationship on look bring have and work level been Our the very the path interactions collaborative We been of to interaction modular with has forward continuing Motiva
their flagship under locations most in newest aesthetic clinic January of Mia in and that them signed high-end to aesthetics, global aesthetic breast On partner. Tokyo; XX one operates have are in in up early world, of our practices first first we the Seishin we of network Ginza. as Roppongi They Plastic so practices category our we two Japan. Aesthetic Clinic an new we a and Mia in Surgery have Seishin is in prestigious their and in creating in the update will the clinic the happy partner Femtech, offer clinic Mia. are provided rollout first
for engaged with Our development launch. teams education medical practice preparation a them and actively are in
without anesthesia With creating breast aesthetics. women their daily of a procedure about aesthetics offered shape in that performed proportions a be conscious solution activities. augmentation, their women consumers, women don't are a is and breasts. in return Mia invasive an we are XX opening Mia, can for to new the whole these of minutes up more a with providing a but new appealing to that easy we general are want By to category group traditional less that than minimally
as demonstrating over proof the Mia and scale partner are bringing opportunity economics. providing to breast potential into the coming look on new higher These this forward Mia, multibillion-dollar that benefiting seeing become. launch our points will the look we be from that into updates it that We efficiency we focused category, to important improved are to and has months. a women are As we surgeons clinics new aesthetics is
expander franchise, positive their post-mastectomy it recon in Flora aesthetic approval Motiva In The of expander of for and announced regulatory Flora continues. November, surgeons our is more breast in with the tissue making reconstruction. breast Motiva Japan. choice feedback rollout and market more we our very Implants In
that Flora in significant in in breast global changing resonate standard breast the reconstruction. a category launching a is at Implants in a step is to reconstruction. with new has commented What with unfortunately neglected clinicians Flora continues is offering what globally Motiva with advances we the market As been in time, much-improved Japanese the many
to allow the aspire. where reconstruction women in that ideals achieve offer step techniques Flora which surgeries will first receive only they to recon and aesthetic initiative that our Labs is breast the aesthetic Establishment tools
device Establishment medical and on reconstruction. responsibility women's health, the opportunity global the a company to has focused breast improve Labs As
that like improve education, we advocacy and to Flora We also new not awareness promote but market in can are to access. engaging efforts only technologies outcomes, bringing are
The are globally in eight One very will significant. lifetime. breast the undergo women a recovery of disease. But in the cancer will as them of few need her from opportunity experience their and reconstruction part
As recon progress will breast be our we meaningful. impact make aesthetic the in initiatives, global
our expect progress of in the Motiva COVID encouraging, to On China, once approval, second first in for restrictions XXXX. approval and lifting more what launch for approval is to make return are this activity we process, also China market market into of in the adoption the and in we in normal can largest we half the but only not regulatory recent for the world. The continue
January, In an XXXX. to This provided growth from works annual the the rate average breast U.S., EMEA, reconstruction in contributions globally. Morgan out Establishment Conference, J.P. outlook for to Labs XX% Healthcare revenue markets. contemplates in and China, and existing at an achieve our it of million we $XXX from
the growth years. many expect of this over growth next layers linear With behind will the target, don't be four we
continue conservative, is suggest that years many XXXX. and layers many growth supported, even well for target also the that will beyond this However,
plan us range next which leading reach is suggests the long for company in for reconstruction. are and a view potential growth to organize. a not our we well and We with breast it the in before target chapter global aesthetics us, within story only become around to providing It provides ready see our but and the
options We new growth will continue women for to and, create world. we doing the transform and opportunities new so, more in importantly, for our markets will create around
I will the call now over turn Raj. to
